In Vivo Activity of Microbial Heparinase

Langer, R.
Linhardt, Robert J.
Larsen, A.K.
Cooney, C.L.
Tapper, D.
Klein, M.
No Thumbnail Available
Other Contributors
Issue Date
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
Full Citation
In Vivo Activity of Microbial Heparinase, R. Langer, R.J. Linhardt, A.K. Larsen, C.L. Cooney, D. Tapper, M. Klein, Transactions of the American Society for Artificial Internal Organs, 28, 387-390 (1982).
Heparin, prepared from mammalian intestinal mucosa, is the most widely used anticoagulant. It has been estimated, however, that the use of heparin leads to complications such as bleeding 8-33% of the time1. Of all prescription drugs, heparin is the drug responsible for the greatest number of deaths in otherwise healthy patients 2. For these reasons, it would be extremely useful to have a method to control blood heparin levels. We propose that this might be accomplished by using heparinase, an enzyme which specifically degrades the anticoagulant activity of heparin. In this report, we discuss the in vivo activity of both free and immobilized heparinase.
Transactions of the American Society for Artificial Internal Organs, 28, 387-390
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
The Linhardt Research Labs.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
The Linhardt Research Labs Online Collection
Rensselaer Polytechnic Institute, Troy, NY